Purchase Order 75F40120P00159

This firm fixed-price purchase order for $18,204.88 was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Genscript USA Inc. to obtain cell lines utilizing CRISPR gene editing technology. Specifically, the contract calls for Genscript to generate knockout HEK293 and HepG2 cell lines of the MMAB and MUT genes to support studies for hereditary disorders of vitamin B12 and methylmalonic acid metabolism. No set-aside designation...

The Department of Health and Human Services Food and Drug Administration awarded a $25,000 firm fixed price purchase order to Life Technologies Corporation for cell line engineering services utilizing the Invitrogen FLP-IN 293 cell line. Life Technologies Corporation is a subsidiary of Thermo Electron Corporation Financial Services Division and will perform the services in Silver Spring, Maryland. The contract runs from August 31, 2023 through August 30, 2024 to provide the FDA with cell line...

This federal contract award, with an ID of HHSN267200800780P, was issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency, to the Texas Institute For Genomic Medicine. The $4,000.00 contract is for the provision of a C57BL/6 embryonic stem cell clone associated with the GALNT2 (MGI: 894694) gene. The contract does not have a set-aside designation and was awarded on July 7, 2008, with a completion date of July 17, 2008. As this is a purchase order...

This purchase order contract was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Life Technologies Corporation for the delivery of 50 vials of human spheroid-qualified hepatocytes. As described in the original solicitation, these liver cells will support the National Institute on Drug Abuse's Antiviral Program for Pandemics by enabling the continued identification of direct-acting antivirals and development of microphysiological systems...

The Department of Health and Human Services' National Institutes of Health National Institute of Child Health and Human Development awarded a firm-fixed-price purchase order contract to Synthego Corporation, a self-certified small disadvantaged business, to create genetically modified cell lines. The $36,300.03 contract requires Synthego to deliver two homozygous and two heterozygous POLR3B cell line clones, as well as two homozygous and two heterozygous POLR3E cell line clones, all derived from...

This is a firm fixed-price contract awarded by the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences to Promega Corporation, a global life sciences company, to develop a JAG-1 HiBiT LX-2 hepatic stellate cell (HSC) line and a NOTCH2 reporter cell line and functional assay. The potential value of the contract is $118,568.00 with a completion date of January 31, 2024. The contract was awarded on May 29, 2023 and was not set...

This $100,491 firm-fixed price purchase order was awarded by the National Institutes of Health (NIH) National Institute of Environmental Health Sciences (NIEHS) to Lonza Walkersville, Inc., a for-profit manufacturer of biological materials and laboratory supplies. The contract is for the delivery of up to 400 vials of cryopreserved No-Spin HepaRG cells, which are specialized cell lines used in toxicology research. This award supports a collaborative project between NIEHS and the Environmental...

This federal contract award was issued by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency, to Life Technologies Corporation (doing business as Thermo Fisher Scientific) for $33,436.00 to procure stable cell line generation services. The period of performance will be from July 31, 2022 to March 31, 2023. This is a firm fixed-price purchase order contract and does not utilize any set-aside designation. Life Technologies Corporation is a manufacturer of scientific...

This is a firm fixed-price purchase order contract awarded by the National Institute of Child Health and Human Development (NICHD), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $21,277.24, is for the generation of a POLH/POLI knockout MRC5SV cell line and other associated services. The contract does not have a set-aside designation. Genscript is a well-established...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $17,450.00 firm fixed price purchase order to Applied Stemcell, Inc. to investigate cellular dysfunction associated with hereditary mutation within the prion gene. The contractor must generate two homozygous clones with the E200K prion gene mutation removed and two clones without the mutation removed, validating pluripotency and gene sequence. This requirement...